Compare Microchip Technology Inc. (MCHP) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs Pfizer Inc — how do they compare? Microchip Technology Inc. trades at $74.67 (market cap $41.01B), while Pfizer Inc trades at $28.01 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.9× Microchip Technology Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and Pfizer Inc for 158 Days on average.
| MCHP | PFE | |
|---|---|---|
Market Cap | $41.01B | $158.56B |
Volume | 9,972,516 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $102.97 | $29.02 |
52-Week Low | $49.02 | $23.67 |
Typical Hold Time | 62 Days | 158 Days |
Enterprise Value | $46.13B | $210.06B |
Dividend Yield | 2.41% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $78.02, down 3.99% today, amid a bearish technical signal. The company shows mixed fundamentals with strong recent earnings beats but a challenging 2025 with negative net income. Valuation metrics appear elevated with P/E of 111.06 and P/S of 8.08. Recent developments include the acquisition of Hailo and expansion of Ethernet and power portfolios targeting automotive and data center markets.
Outlook remains cautiously optimistic with analyst consensus at $110.50 (41% upside) and no sell ratings. Key opportunities include AI infrastructure demand and inventory normalization, while risks include high debt levels, competitive pressures, and semiconductor cycle volatility. The stock's performance hinges on execution of growth initiatives and market conditions.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
